The FDA is extending the comment period for two draft guidances because of next week’s scheduled maintenance on the Federal Erulemaking portal. The extensions apply to draft guidances on special protocol assessments and the development of direct-acting antiviral drugs to treat hepatitis C infections. Both drafts were published in the Federal Register May 4. Comments are now due by July 19.